ESMO Sarcoma and Rare Cancers Congress 2023

Lugano 20 March 2023 - 22 March 2023

Surgery, but not chemo, may benefit patients with rare ovarian neoplasms

05 May 2023 by

Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.

05 May 2023

Larotrectinib reduces morbidity, need for aggressive therapies in children with IFS

28 Apr 2023 by

In the EPI-VITRAKVI study, the TRK* inhibitor larotrectinib reduces morbidity and the need for aggressive local therapies in children with infantile fibrosarcoma (IFS) compared with the current standard of care (SoC).

28 Apr 2023

Chemo beneficial in node-positive appendix adenocarcinoma

13 Apr 2023 by

Chemotherapy appears to confer survival advantage in patients with appendix adenocarcinoma who have node-positive tumours, according to a study presented at ESMO Sarcoma 2023.

13 Apr 2023

Ripretinib improves survival in advanced gastrointestinal stromal tumours

11 Apr 2023 by

Treatment with ripretinib provides a prolonged clinical and radiological benefit in patients with advanced gastrointestinal stromal tumours (GIST) within the expanded access program (EAP) in the UK, as shown in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

11 Apr 2023

Eribulin, trabectedin active against pleomorphic liposarcoma

07 Apr 2023 by

Eribulin and trabectedin show significant antitumour activity in advanced pleomorphic liposarcoma as compared with conventional chemotherapy, according to retrospective data from the Gustave Roussy cancer centre presented at ESMO SARCOMA 2023.

07 Apr 2023

Second-line bevacizumab plus irinotecan extends survival in glioblastoma

05 Apr 2023 by

The combination of bevacizumab and irinotecan (BEV+IRI) as second-line treatment of glioblastoma (GBM) results in better median progression-free (PFS) and overall survival (OS) when compared with historical controls, and its toxicity profile is comparable to published data, reports a study.

05 Apr 2023